Grant: Doctoral Award - Doctoral Foreign Study Award (DFSA)
Direct Payment
$105,000.00
Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Novel Therapeutics for Schizophrenia: Determining the Mechanisms of Action Underlying Cognition-enhancing and Antipsychotic-like Effects
FY 2015-16
Summary
Schizophrenia is a debilitating, mental illness that affects 1% of Canadians and is associated with positive (e.g. hallucinations), negative (e.g. flattened affect), and cognitive (e.g. impaired working memory) symptoms. Current drugs are effective at ameliorating positive symptoms but are ineffective at treating the negative and cognitive symptoms, failing to reintegrate patients into society. Accumulating evidence implicates a disruption in glutamate signalling, the major excitatory molecule in the nervous system, in the pathophysiology of schizophrenia. Recently, a novel class of drugs termed positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 5 (mGlu5), a protein that responds to glutamate, has been shown to partially restore proper glutamate signalling in the brain. These PAMs have emerged as an exciting therapeutic for the treatment of schizophrenia as they display both antipsychotic-like and cognition-enhancing effects in rodent models. Activation of mGlu5 in the hippocampus, a brain region responsible for spatial and episodic memory, may explain the cognition-enhancing effects of these drugs. The aim of my dissertation is to investigate the molecular signalling pathways that are activated in the hippocampus by mGlu5 PAMs to determine which pathways result in cognition-enhancing effects and which contribute to adverse effects. Our lab has recently developed multiple mGlu5 PAMs that activate different signalling pathways, which I will use as tools to investigate the relative contributions of each pathway to the molecular forms of learning and memory (i.e. synaptic plasticity) as well as to rodent behaviour. The ultimate goal of my research is to improve the discovery and development of mGlu5 PAM clinical candidates that could significantly reduce the financial burden of mental health illness on the economy and ultimately improve the lives of people living with schizophrenia.
Department
Program
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Recipient
Location
Tennessee, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
347886
Name
Maksymetz James
Region
Tennessee
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Novel Therapeutics for Schizophrenia: Determining the Mechanisms of Action Underlying Cognition-enhancing and Antipsychotic-like Effects
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Keyworddelim
Antipsychotics; Brain Function; Cognition; Drug Development; Electrophysiology; Metabotropic Glutamate Receptors; Positive Allosteric Modulators; Schizophrenia; Signal Bias; Synaptic Plasticity
Abstract
Schizophrenia is a debilitating, mental illness that affects 1% of Canadians and is associated with positive (e.g. hallucinations), negative (e.g. flattened affect), and cognitive (e.g. impaired working memory) symptoms. Current drugs are effective at ameliorating positive symptoms but are ineffective at treating the negative and cognitive symptoms, failing to reintegrate patients into society. Accumulating evidence implicates a disruption in glutamate signalling, the major excitatory molecule in the nervous system, in the pathophysiology of schizophrenia. Recently, a novel class of drugs termed positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 5 (mGlu5), a protein that responds to glutamate, has been shown to partially restore proper glutamate signalling in the brain. These PAMs have emerged as an exciting therapeutic for the treatment of schizophrenia as they display both antipsychotic-like and cognition-enhancing effects in rodent models. Activation of mGlu5 in the hippocampus, a brain region responsible for spatial and episodic memory, may explain the cognition-enhancing effects of these drugs. The aim of my dissertation is to investigate the molecular signalling pathways that are activated in the hippocampus by mGlu5 PAMs to determine which pathways result in cognition-enhancing effects and which contribute to adverse effects. Our lab has recently developed multiple mGlu5 PAMs that activate different signalling pathways, which I will use as tools to investigate the relative contributions of each pathway to the molecular forms of learning and memory (i.e. synaptic plasticity) as well as to rodent behaviour. The ultimate goal of my research is to improve the discovery and development of mGlu5 PAM clinical candidates that could significantly reduce the financial burden of mental health illness on the economy and ultimately improve the lives of people living with schizophrenia.
Competitiondate
201510
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Maksymetz, James
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~